BBOT to Participate in Upcoming Investor Healthcare Conferences

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT), headquartered in South San Francisco, is set to engage with investors through its participation in two upcoming healthcare conferences. As a clinical-stage biopharmaceutical company, BBOT focuses on the development of novel therapeutic solutions targeting malignancies associated with RAS-pathway and PI3K oncogenes, which play a critical role in the progression of various cancers. These conferences provide a platform for the company to showcase its innovative pipeline and strategic vision aimed at improving outcomes for patients suffering from RAS and PI3K-driven tumors.

BBOT's leadership team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 10:40 a.m. ET, followed by a presentation at the Leerink Global Healthcare Conference on March 10, 2026, at 10:00 a.m. ET. Investors and interested parties can access live webcasts of both presentations via the “Events” page of BBOT’s investor website. These webcasts will remain available for replay for at least 90 days after the events, ensuring that stakeholders have the opportunity to engage with the valuable insights shared during the presentations.

The company emphasizes its commitment to advancing a next-generation pipeline that seeks to tackle the most prevalent oncogenes in human tumors. For additional details regarding BBOT’s initiatives, investors are encouraged to visit their website or connect via LinkedIn. With a focus on delivering transformative healthcare solutions, BBOT continues to position itself as a key player in the oncology sector. For further inquiries, interested parties can reach out to Investor Contact Heather Armstrong or Media Contact Jake Robison for additional information.

BridgeBio Oncology Therapeutics, Inc. (BBOT) is making notable strides in the biopharmaceutical sector, particularly in addressing RAS-pathway malignancies. With its upcoming presentations at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference, investors should consider this an opportune moment to evaluate the company’s potential.

BBOT’s focus on targeting the RAS and PI3K pathways places it at the forefront of addressing significant unmet medical needs in oncology. Given that these pathways are implicated in various cancers, the market's demand for effective therapies is substantial. The company’s clinical-stage position suggests it is effectively leveraging its innovative pipeline to potentially capture significant market share in oncology therapeutics.

Investors should specifically watch for insights during the presentations regarding pipeline advancements, trial results, and strategic partnerships that could elevate BBOT’s visibility and market position. The timing of these presentations coincides with a broader sector interest in biotech, especially as investors seek opportunities in companies capable of delivering next-generation treatments. Live webcasts will allow for real-time analysis of BBOT’s strategic direction and financial health, with recorded sessions providing a valuable resource for ongoing evaluation.

Moreover, as BBOT engages with the investment community, it may attract institutional interest, potentially boosting stock performance. Investors should also monitor industry trends associated with RAS-targeted therapies and broader oncology market shifts to gauge potential market reaction post-conference.

In summary, BBOT presents an intriguing opportunity for investors looking to engage with a company positioned in a high-growth area within biopharma. Continued attention to the company's updates and its interactions at these conferences will be key to assessing its investment viability.